# Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

> **NCT03381430** · NA · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT03381430
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06
- **Primary completion:** 2023-03
- **Final completion:** 2025-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2017-12-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381430, "Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03381430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*